Longevity Medicine
AURELIA / COLLECTION

Longevity Medicine

Four proposed coordination services with clear scope and illustrative fees. Medical decisions and treatment remain with licensed providers; hospital, test and treatment fees are separate.

HEALTHSPAN / WHY IT MATTERS

More healthy years More possibility

An introduction to longevity medicine, its demand context and the technologies being explored.

What is longevity medicine

A field connecting ageing biology, prevention, functional assessment and personal health planning. Its focus is healthspan: years lived with health, independence and useful function.

Why pay attention now

Longer life does not automatically mean longer good health. Maintaining mobility, cognition and metabolic health can help protect everyday choices and quality of life.

Everyday signals
Everyday signals · concept image
Biology & discovery
Biology & discovery · concept image
Personal goals
Personal goals · concept image
Global population aged 60+
2020: 1 bn; 2030 forecast: 1.4 bn; 2050 forecast: 2.1 bn00.631.251.882.520201 bn2030 forecast1.4 bn2050 forecast2.1 bn
View exact data
MeasurementValue
20201 bn
2030 forecast1.4 bn
2050 forecast2.1 bn

WHO, 1 October 2025. Population figures, not medical market size.

WHO projects that one in six people worldwide will be aged 60+ by 2030; the share rises from 12% in 2015 to 22% in 2050.

RELATED ECONOMY / DIFFERENT SCOPE

Demand context, with a clear denominator

$7.5T2025 wellness economy6.36% of global GDP
$10.9T2030 GWI forecast7.21% of global GDP

GWI’s report, released 11 November 2026, covers eleven wellness sectors. These values are not the market size or future share of longevity medicine. A single comparable worldwide market-share figure for longevity medicine is not established here.

Purpose goals and realistic outcomes

The goal is better function and informed prevention, not a guaranteed age reversal or a fixed number of extra years. Aurelia can help define goals, organise existing information and connect professional resources; clinicians assess diagnosis, testing and treatment.

Six technology and practice themes

01 / Established practice varies by assessment

Risk & functional assessment

Cardiometabolic risk, mobility, strength, cognition and lifestyle assessment.

02 / Clinical validation differs

Multi-omics & biomarkers

Genetic, epigenetic, protein and metabolic data; biological-age tools require use-specific validation.

03 / Monitoring & feedback

Digital health & wearables

Activity, sleep and physiological feedback support observation; devices alone do not diagnose.

04 / Foundation of practice

Lifestyle medicine

Movement, nutrition, sleep and appropriate management of known risk factors.

05 / Research stage varies

Ageing-mechanism research

Senescence, inflammation, metabolism and autophagy; experimental results are not general anti-ageing prescriptions.

06 / Indication-specific status

Regenerative & cell technologies

Stem cells, iPSCs and cell replacement, interpreted by product, indication and jurisdiction.

Editorial themes informed by geroscience, not an official universal six-technology classification.

LONGEVITY / DAILY PRACTICE

How do we put longevity medicine into practice

Begin with sustainable habits and appropriate professional assessment, rather than chasing one test or intervention. Food, movement, rest and follow-up form a practical starting point; personal goals and medical needs guide the next steps.

01Eat with variety
02Move within your ability
03Keep a regular rhythm
04Review relevant risks
05Build habits you can keep
Read How to Eat →
4 / ITEMS TO EXPLORE

Longevity Medicine

View bag (0) →
Pre-sale enquiries. Product specifications, availability, delivery and order acceptance require confirmation. Online payments are not connected.
Assessment Visit Preparation
AURELIA

Assessment Visit Preparation

Organise existing report indexes, appointment documents and questions in a visit preparation pack; no diagnosis or test prescription.

Illustrative image

Pre-sale price by enquiry

Business customers: email or ask our assistant for a quote

AURELIA / PARTNERSHIP DEVELOPMENT

Longevity Clinic Investment & Partnership

A feasibility and partnership proposal, not an operating clinic or investment offer.

Care model

Risk-based preventive care, evidence-based screening, nutrition and movement education and longitudinal follow-up. Clinical services are delivered by locally licensed professionals; no unvalidated anti-ageing treatment packages.

Partner roles

Medical partners lead clinical governance; operating partners evaluate venues and staffing; investors assess phased financing. Joint development, institutional collaboration and operating support are options, subject to local ownership rules.

Feasibility before funding

Start with demand and city research, then service scope and venue comparisons, staffing and capital/operating budget, local legal review and licensing assessment. Fundraising terms follow a documented feasibility decision.

Quality & clinical boundaries

Define clinical accountability, consent, privacy, incident review and referral for findings. China, Japan and US states have distinct clinic and ownership requirements; an education business is not a medical licence.

What to bring to a discussion

Proposed city, legal entity, licences, clinical team, venue conditions, funding scope and experience. A confidential review precedes any medical or investment commitment.

Questions & answers

Is the proposed clinic already operating?

No. It is a feasibility and partnership proposal. Location, clinical team, funding and local permissions are not confirmed.